Meyers J, Hoog M, Mody R, Yu M, Hasenour C, Davis KL. Burden of cardiovascular disease and cardiovascular (CV) risk in patients with Type 2 diabetes mellitus (T2DM): an analysis of a US health insurance database. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S115. doi: 10.1016/j.jval.2020.04.371
Lewis S, Price M, Dwyer KA, O'Brien S, Heekin RD, Yates PJ, Beverland D, Mordin M. Development of a scale to assess performance following primary total knee arthroplasty. Value Health. 2014 Apr 21;17(4):350-9. doi: 10.1016/j.jval.2014.01.006
Ronquest N, Mladsi D, Hopley C, Edgell E. The economic value of an innovative knee implant system for total knee arthroplasty. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 6, 2013. New Orleans, LA. [abstract] Value Health. 2013 May; 16(3):A225.
Hicks K, Earnshaw S, McDade C, Shaw JW, Cifaldi MA. Benefit-risk analysis of adalimumab and alternative treatments for moderate to severe rheumatoid arthritis. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 13, 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A439-40.
Poulos C, Hauber AB, Gonzalez JM, Ogale S, Turpcu A. Patient trade-offs between frequency and duration of biologic treatments for rheumatoid arthritis. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 6, 2012. [abstract] Value Health. 2012 Jun; 15(4):A42.
Poulos C, Hauber AB, Gonzalez JM, Ogale S, Turpcu A. Patient trade-offs between frequency and duration of biologic treatments for rheumatoid arthritis. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A42.
Wilburn J, McKenna S, Crawford SR, Perry-Hinsley D, Bayat A. Determining the true impact of dupuytren's disease: a qualitative study. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 2011. Madrid, Spain. [abstract] Value Health. 2011 Nov; 14(7):A314-5.
Wilburn J, McKenna SP, Twiss J. Further developments of the rheumatoid arthritis quality of life scale (RAQoL). Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, Spain. [abstract] Value Health. 2009 Oct; 12(7):A447-8. doi: 10.1016/S1098-3015(10)75215-3
von Scheele B, David K, Gaffney L, Niculescu L, Verburg KM. The total cost of treatment and the cost-effectiveness of valdecoxib vs diclofenac in the treatment of patients with osteoarthritis (OA) of the hip and/or knee. Poster presented at the 2004 ISPOR 7th Annual European Congress; October 24, 2004. [abstract] Value Health. 2004 Nov; 7(6):661.
Alten RH, von Scheele B, Gaffney L, Maciver F, Niculescu L. Cost-effectiveness of valdecoxib compared to diclofenac in patients with rheumatoid arthiritis (RA) in the United Kingdom (UK) and Germany. Poster presented at the 2004 ISPOR 7th Annual European Congress; October 24, 2004. [abstract] Value Health. 2004 Nov; 7(6).
von Scheele B, DePlatchett J, Gaffney L, Peña BM, Niculescu L. The total costs of treatment with valdecoxib compared to generic diclofenac are similar in patients with rheumatoid arthritis in Germany. Poster presented at the 2003 ISPOR 6th Annual European Congress; November 9, 2003. Barcelona, Spain. [abstract] Value Health. 2003 Nov; 6(6):725-6.